Filing Details

Accession Number:
0001209191-12-003317
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2012-01-11 17:12:20
Reporting Period:
2011-12-20
Filing Date:
2012-01-11
Accepted Time:
2012-01-11 17:12:20
Original Submission Date:
2011-12-22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235007 Endocyte Inc ECYT Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1267980 V Management Ventures Sanderling 400 S. El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
1429588 Vi Management Ventures Sanderling 400 S. El Camino Real, Suite 1200
San Mateo CA 94402
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-12-20 22,200 $3.20 52,966 No 4 P Indirect By Sanderling Ventures Management VI
Common Stock Acquisiton 2011-12-21 22,200 $3.16 75,166 No 4 P Indirect By Sanderling Ventures Management VI
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Sanderling Ventures Management VI
No 4 P Indirect By Sanderling Ventures Management VI
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 189,003 Indirect By Sanderling Ventures Management V
Footnotes
  1. The form 4 is being amended to correct the number of shares acquired which was incorrectly reported in the original filing.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.14 to $3.27, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.
  4. Fred Middleton is the owner of Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership and he may be deemed to have voting and investment power over shares held of record by Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership.
  5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.10 to $3.21, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.